Abstracts Archive - Page 228 of 1683 - ATC Abstracts

2021 American Transplant Congress
Development of De-novo Malignancies After Kidney and/or Pancreas Transplantation in Diabetic Patients
A. Gruessner, S. Saggi, J. Renz, R. Gruessner
SUNY Downstate Medical Center, Brooklyn, NY
*Purpose: Transplantation of a kidney (KTA), pancreas (PTA), or a simultaneous pancreas-kidney (SPK) in a patient with end-stage organ failure is a lifesaving treatment. Patient…
2021 American Transplant Congress
Corticosteroid Reintroduction in Urban Simultaneous Kidney-pancreas Transplant Recipients Following an Early Corticosteroid Withdrawal Protocol
D. Pierce, P. West-Thielke, M. Campara, I. Tang, M. Spaggiari, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Approximately 30% of patients who undergo simultaneous kidney-pancreas (SKP) transplant are maintained on dual therapy with tacrolimus and mycophenolate. Long-term implications of steroid reintroduction…
2021 American Transplant Congress
The Impact of Tacrolimus IPV and TTR on the Development of De Novo Donor-specific Antibodies in Kidney Transplant Recipients
D. Xu¹, K. Richards¹, K. Zheng¹, H. Patel², F. Cardarelli², J. A. Pena³, A. Aala²
¹Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, ²Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ³Pathology, Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: High intrapatient variability (IPV) and low time in therapeutic range (TTR) of tacrolimus (TAC) may increase the risk of developing de novo donor-specific antibodies…
2021 American Transplant Congress
Donor Derived Cell Free DNA Identifies Rejection in Simultaneous Pancreas Kidney Transplant Recipients
M. Williams¹, S. Ghosh², L. L. Jenkins², M. Hertl¹, S. Saltzberg³, V. Peev³, E. Chan¹, E. Hollinger¹, E. Schadde¹, O. Olaitan¹
¹Department of Surgery, Rush University Medical Center, Chicago, IL, ²CareDx, Inc., Brisbane, CA, ³Department of Internal Medicine, Rush University Medical Center, Chicago, IL
*Purpose: Increased level of donor-derived cell-free DNA (dd-cfDNA) has proven to be a sensitive marker for allograft rejection after solid organ transplant, particularly heart and…
2021 American Transplant Congress
Seasonality of Mortality for Solid Organ Waitlist Candidates
J. Miller, D. Musgrove
SRTR, Minneapolis, MN
*Purpose: Analysis of the impact of policies or natural occurrences on transplant system outcomes requires comparison of a treatment (post-policy) period to a control (pre-policy)…
2021 American Transplant Congress
Racial/ethnic Disparities Among Renal Transplant Recipients with Diabetes, Hypertension, and/or Dyslipidemia Due to Medicare Part D Star Ratings Criteria
M. Chisholm-Burns¹, C. Spivey¹, C. Tsang¹, L. E. Hines², J. Wang¹
¹University of Tennessee Health Science Center College of Pharmacy, Memphis, TN, ²Pharmacy Quality Alliance, Alexandria, VA
*Purpose: Medication adherence is critical to positive outcomes in renal transplant recipients (RTRs), and policies have been designed encouraging adherence. For example, Medicare Part D…
2021 American Transplant Congress
A Multi-institutional Study of Renal Outcomes in Uterus Transplantation
D. Sawinski¹, L. Johannesson², J. Kristen³, J. Fronek³, P. Porrett⁴
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²Department of Surgery, Baylor University Medical Center, Dallas, TX, ³Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ⁴University of Alabama at Birmingham, Birmingham, AL
*Purpose: Pregnancy and calcineurin inhibitor-based immunosuppression represent potential renal stressors for uterus transplant (UTx) recipients, many of whom have Mayer-Rokitanksy-Kuster-Hauser (MRKH) syndrome and associated renal…
2021 American Transplant Congress
Combined CD11b/CD40 Blockade is Superior to CD40 Blockade Alone in Prolonging Survival in Pig-to-Nonhuman Primate Renal Xenotransplantation
D. A. Faber¹, B. Lovasik¹, A. Matar¹, C. Breeden¹, S. Kim¹, A. Adams²
¹Surgery, Emory University School of Medicine, Atlanta, GA, ²Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Blockade of the CD40/CD154 pathway is highly effective in preventing rejection in pig-to-nonhuman primate (NHP) xenotransplantation models. Clinical translation of anti-CD154 mAbs, however, has…
2021 American Transplant Congress
A Single Nucleotide Polymorphism within the FCGR3A 158 F/V Gene is Associated with Decreased Survival of Renal Allografts with Chronic Active Antibody-Mediated Rejection
N. H. Litjens, A. M. Peeters, J. A. Kal-van Gestel, M. Klepper, M. G. Betjes
Internal Medicine, Nephrology and Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands
*Purpose: Long-term allograft survival has shown little improvement over the last decades. An important factor compromising long-term allograft survival in kidney transplantation is chronic active…
2021 American Transplant Congress
Baseline Levels of Dd-cf Dna After Pancreas Transplantation: Using Dd-cfdna as an Indicator for Pancreas Rejection and Biopsy Avoidance
A. Yoo, I. Qian, A. Riedel, C. Cazac, A. Bartosic, J. S. Bromberg, J. Scalea
Department of Surgery, Division of Transplant, University of Maryland School of Medicine, Baltimore, MD
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) testing, which has been previously validated for monitoring kidney transplant (KTx) rejection, may provide an alternative to pancreas biopsy that…